Mini Review Volume 11 Issue 2
Department of Otolaryngology, the Forth Hospital Affiliated to Harbin Medical University, China
Correspondence: Zhao Dong, Department of Otolaryngology, the Forth Hospital Affiliated to Harbin Medical University, Harbin 150000, China
Received: February 23, 2018 | Published: March 14, 2018
Citation: Lin-lin ZDD, Pin X, Bin Z et al. Therapeutic effect of Mora combined with vasodilators for sudden hearing loss. Int J Complement Alt Med. 2018;11(2):53 – 56. DOI: 10.15406/ijcam.2018.11.00366
Objective To investigate the therapeutic effect of Mora combined with vasodilators for sudden hearing loss.
Methods: 120 patients (128 ears) suffering from sudden hearing loss and hospitalized in our department from Oct 2013 to Oct 2016 were included. According to the admission time, all the patients were randomly divided into two groups. 60 cases (66 ears) in group A received treatment of Mora combined with vasodilators, glucocorticoids and neurotrophic drugs. 60 cases (62 ears) in group B were treated by using vasodilators, glucocorticoids and neurotrophic drugs. The treatment course was 12 days for both groups. Their therapeutic effects were observed and compared.
Results: The total effective rate of group A was 90.91 %, which was higher than that of group B (74.19%). The difference of total effective rate between both groups was statistically significant (P<0.05).
Conclusion: Mora combined with vasodilators can significantly improve the therapeutic effect without any side effect which is worth applying and recommending in the treatment of sudden hearing loss.
Keywords: sudden hearing loss, mora, biotherapy, combined treatment
Sudden hearing loss (SHL), also called idiopathic sudden sorineural hearing loss (ISSHL), refers to sudden neural hearing loss accompanied possibly with tinnitus, dizziness, aural fullness and other clinical symptoms, caused by uncertain reasons within 3 days. SHL is a common emergency for otolaryngology and its morbidity is on the rise in recent years.1 Causes and pathogenesis of SHL are complicated and unclear, which could be connected with the microcirculation malfunction of inner ears, Ménière disease, viral infection, immunity and vascular disease.2 Even though, progress has been made to a certain extent in the treatment and efficacy evaluation of SHL, there is no clear standard, and most of the treatments perform poorly in prognosis.3 This research mainly discusses the therapeutic effect of Mora combined with vasodilators for SHL.
General data
120 SHL patients (128 ears) treated in our department from October 2013 to October 2016 were selected as subjects for the research. All patients received CT scans of the temporal bone and MRI examinations of the internal auditory canal, and had no organic diseases. Concurrently, patients with past history of drug allergies or diabetes, who are unable to use the combined treatment of glucocorticoid, and those with major organic failures were excluded from the research. Patients were numbered and marked according to their visitation date and were randomly divided into two groups by their marked numbers (odd or even). 60 cases (66 ears) in group A received treatment of Mora combined with vasodilators, glucocorticoids and neurotrophic drugs. 60 cases (62 ears) in group B were treated with the combined use of vasodilators, glucocorticoids and neurotrophic drugs. General conditions of patients during admission were not statistically different (P>0.05) in Table 1.
Clinic Data |
Group A |
Group B |
t |
P |
Number of Cases |
60 |
60 |
- |
- |
Number of Ears |
66 |
62 |
- |
- |
Gender |
|
|
|
|
Male |
28 |
26 |
2.1 |
0.112 |
Female |
32 |
34 |
1.4 |
0.139 |
Period (d) |
|
|
|
|
≤3 |
16 |
28 |
1.6 |
0.145 |
4~7 |
24 |
16 |
1.2 |
0.223 |
>7 |
20 |
16 |
3.6 |
0.439 |
Age (years) |
|
|
|
|
<30 |
10 |
12 |
3.1 |
0.516 |
30~60 |
22 |
24 |
2.1 |
0.241 |
>60 |
28 |
24 |
1.7 |
0.158 |
SHL Type |
|
|
|
|
HF Down |
22 |
20 |
2.9 |
0.154 |
LF Down |
10 |
14 |
2.2 |
0.562 |
Plain Down |
14 |
12 |
2.8 |
1.178 |
THL |
14 |
14 |
2. 1 |
0.397 |
Complication |
|
|
|
|
Dizziness |
30 |
22 |
2.9 |
0.090 |
Tinnitus |
50 |
44 |
1.5 |
0.110 |
Table 1 Comparison of General Conditions (Case )
Treatment
All patients received combined treatment with regular care and psychological counseling, with 12 days as one treatment course. Drug & usage: Jinnaduo (Extract of Ginkgo Biloba Leaves Tablets) 25mg + normal saline 250 ml intravenous injection, once a day for 12 days; hexadecadrol 10mg/d for three days, then 5mg/d till the 10th day; 52 patients with dizziness were treated with betahistine tablets (Minshilang, 6mg/tablet), 1 tablet is orally taken three times a day. Group A were added with the use of biological therapy of Mora for once every day, 40 min on each occasion, with 12 days as one treatment course. All patients in Group A and Group B received pure tone audiometry every 4 days during treatment. All treatments lasted for only one treatment course.
Evaluation of effects
Treatment efficacy for hearing loss was evaluated according to the 2015 Guide for Diagnosis and Treatment of SHL,4 which includes Cured: damaged hearing ability is restored to normal or reach normal level, or restored to its previous level; Effectual: average damaged hearing ability is improved by more than 30dB; Effective: damaged hearing ability is improved by 15 to 30 dB; Ineffective: damaged hearing ability is improved by less than 15 dB or declines. Total efficiency = (cured ears + effectual ears + effective ears)/total ears *100%.
Statistical processing
Data was gathered and processed using statistical software SPSS 17.0; measurement data was shown as; inter-group comparison is tested by t and inter-group rate x2; difference is statistically significant only when P< 0.05.
After one treatment course, the total effective rate of Group A was 90.91%, higher than that of Group B which was 74.19%. The difference was statistically significant (=0.02) in Table 2. No side effects were observed during treatment in both groups.
Group |
Ears |
Cured |
Effectual |
Effective |
Ineffective |
Total effective rate |
Group A |
66 |
28 |
18 |
14 |
6 |
90.91* |
Group B |
62 |
18 |
12 |
16 |
16 |
74.19 |
Table 2 Comparison of Therapeutic Effect (Ears, %)
Note: *P = 0.02, compared with Group B.
Clinical treatment for SHL mainly uses glucocorticoids, vasodilators, anticoagulants and HPO. It has been found that glucocorticoids could trigger stress reaction with certain hormone receptors in the cytoplasm, which further alleviates SHL. Such hormone receptors5,6 widely exist in vestibule and cochlea, and mostly concentrate in the spiral ligament. Glucocorticoids and relevant receptors generate hormone-receptor compound to enter the cell nucleus. By increasing the transcription of anti-inflammatory genes and decreasing that of the inflammatory genes, it alleviates inflammation and further prevents other related illness. Therefore, glucocorticoids combined with vasodilators are mainly used to treat SHL.7–9
Treatment in combination with HPO or anticoagulants was proven effective for some patients.10,11 But not all SHL patients are suitable to undergo the treatment of glucocorticoids, especially for the aged as it often triggers other systematic diseases. Also, elder patients are more sensitive to the side effects of hormone and hormone on its own cannot be used for a long period of time.12–15 Patients in this research all received hormone treatment for one course and reported no side effects. Clinical researchers found that TCM is more suitable for treating SHL to some extent.16 Mora treatment is based on and developed from quantum physics, electromagnetic oscillation theory, bio-electronic environment theory, TCM channel and collateral channels & acupuncture theory and natural homeopathy.
As is known to all, the human body is composed of millions of cells. Similar cells gather together to form human organs and different organs collaborate to ensure the regular running and health of the body. Also, each cell has its own magnetic field and only when they combine and collaborate can the body form a regular bio-magnetic field. When the body gets ill or certain organs fail, such bio-magnetic field would change and when the illness gets worse, corresponding symptoms would appear in the body. Mora treatment mainly adopts the technology of resonance of biological electromagnetic waves and is developed based on the theory that biologic cells have biological electromagnetic field effect and the material has wave-particle duality. Mora separates and analyzes irregular bio-magnetic fields of human body, and uses the electromagnetic wave system of the body to treat diseases. It could filter the electromagnetic waves of the human body, separate them into healthy ones and pathologic ones and use the former to balance the latter to achieve balance of the system and help the body to heal itself.
During Mora treatment, patients only need to sit with their hands separated and holding positive and negative electrode bars with their feet bared on the pedal, and Mora operators would then proceed with the rest of the treatment. There is no taking of any injection or drug. Mora, as a noninvasive treatment, could be used as a vital means to treat SHL for the time being. This research finds that the therapeutic effect of Mora combined with vasodilators for treating SHL could be 90.91%, significantly higher than that of simply using vasodilators combined with glucocorticoids at 74.19%, indicating that the former treatment outperforms the latter.
As a noninvasive treatment, Mora adjusts the state of body to actively prevent invasion of illness and could be a vital means for treating SHL. To sum up, Mora combined with vasodilators can significantly improve the therapeutic effect which is worth applying and recommending in the treatment of SHL.
None
Author declares there is no conflict of interest towards this manuscript.
©2018 Lin-lin, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.